Form 144 Arcellx For: 13 January
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arcellx Inc (ACLX)
Arcellx Inc stock price live, this page displays NASDAQ ACLX stock exchange data. View the ACLX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arcellx Inc real time stock price chart below.
What Is the Arcellx Inc Stock Price Today?
The Arcellx Inc stock price today is 68.83.
What Is the Stock Symbol for Arcellx Inc?
The stock symbol for Arcellx Inc is "ACLX."
What Stock Exchange Does Arcellx Inc Trade On?
Arcellx Inc is listed and trades on the NASDAQ stock exchange.
Is Arcellx Inc a Good Stock to Buy?
Determining whether Arcellx Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACLX quote. (ISIN: US03940C1009)
What Is the Arcellx Inc Stock Price Today?
The Arcellx Inc stock price today is 68.83.
What Is the Stock Symbol for Arcellx Inc?
The stock symbol for Arcellx Inc is "ACLX."
What Stock Exchange Does Arcellx Inc Trade On?
Arcellx Inc is listed and trades on the NASDAQ stock exchange.
Is Arcellx Inc a Good Stock to Buy?
Determining whether Arcellx Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACLX quote. (ISIN: US03940C1009)
NASDAQ
Currency in USD
68.83
+2.08(+3.11%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
65.10
69.65
52 wk Range
47.86
94.07
ACLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
65.1069.65
52 wk Range
47.8694.07
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ACLX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
112.35
Upside
+63.23%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Arcellx receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Arcellx CMO Heery sells $487k in shares
- Investing.com
- Arcellx (ACLX) CMO Heery sells $393k in shares
- Investing.com
- Form 144 Arcellx For: 13 January
- Investing.com
- Arcellx CMO Heery sells $487k in shares
- Investing.com
- Arcellx (ACLX) CMO Heery sells $393k in shares
- Investing.com
- Form 144 Arcellx For: 12 January
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Arcellx Inc Company Profile
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Arcellx Inc SWOT Analysis
Promising Myeloma Therapy | Arcellx's anito-cel shows potential best-in-class efficacy and safety in multiple myeloma treatment, with 97% overall response rate in clinical trials |
Market Disruption Ahead | Analysts project CAR-T therapies could capture 30% of multiple myeloma market, positioning Arcellx for significant growth in a competitive landscape |
Financial Horizon | Despite current losses, Arcellx maintains strong liquidity. Analysts forecast EPS of -$1.47 for FY 2023, -$1.53 for FY 2024, and -$4.27 for FY 2025 |
Bullish Outlook | Analysts maintain strong buy consensus with high target of $134. Barclays and Canaccord set price targets at $115 and $121, respectively |
Compare ACLX to Peers and Sector
Metrics to compare | ACLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACLXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.4x | −1.7x | −0.6x | |
PEG Ratio | 0.04 | 0.03 | 0.00 | |
Price/Book | 9.1x | 1.2x | 2.6x | |
Price / LTM Sales | 111.6x | 9.5x | 3.4x | |
Upside (Analyst Target) | 67.8% | 568.8% | 40.3% | |
Fair Value Upside | Unlock | 23.5% | 4.8% | Unlock |
Analyst Ratings
18 Buy
2 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 112.35
(+63.23% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
-0.99 / -0.96
Revenue / Forecast
4.90M / 11.23M
People Also Watch
FAQ
What Is the Arcellx (ACLX) Stock Price Today?
The Arcellx stock price today is 68.83
What Stock Exchange Does Arcellx Trade On?
Arcellx is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Arcellx?
The stock symbol for Arcellx is "ACLX."
What Is the Arcellx Market Cap?
As of today, Arcellx market cap is 3.86B.
What Is Arcellx's Earnings Per Share (TTM)?
The Arcellx EPS (TTM) is -3.94.
When Is the Next Arcellx Earnings Date?
Arcellx will release its next earnings report on Feb 25, 2026.
From a Technical Analysis Perspective, Is ACLX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Arcellx Stock Split?
Arcellx has split 0 times.
How Many Employees Does Arcellx Have?
Arcellx has 163 employees.
What is the current trading status of Arcellx (ACLX)?
As of Jan 14, 2026, Arcellx (ACLX) is trading at a price of 68.83, with a previous close of 66.75. The stock has fluctuated within a day range of 65.10 to 69.65, while its 52-week range spans from 47.86 to 94.07.
What Is Arcellx (ACLX) Price Target According to Analysts?
The average 12-month price target for Arcellx is USD112.35294, with a high estimate of USD134 and a low estimate of USD88. 18 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +63.23% Upside potential.
What Is the ACLX Premarket Price?
ACLX's last pre-market stock price is 66.66. The pre-market share volume is 90.00, and the stock has decreased by -0.09, or -0.13%.
What Is the ACLX After Hours Price?
ACLX's last after hours stock price is 65.74, the stock has decreased by -1.01, or -1.51%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.